PL3233857T3 - Stałe postacie skondensowanych heteroaromatycznych pirolidynonów - Google Patents

Stałe postacie skondensowanych heteroaromatycznych pirolidynonów

Info

Publication number
PL3233857T3
PL3233857T3 PL15831150T PL15831150T PL3233857T3 PL 3233857 T3 PL3233857 T3 PL 3233857T3 PL 15831150 T PL15831150 T PL 15831150T PL 15831150 T PL15831150 T PL 15831150T PL 3233857 T3 PL3233857 T3 PL 3233857T3
Authority
PL
Poland
Prior art keywords
solid state
state forms
fused heteroaromatic
pyrrolidinones
heteroaromatic pyrrolidinones
Prior art date
Application number
PL15831150T
Other languages
English (en)
Inventor
Rongliang Chen
Tomonori ICHIBAKASE
Chunrong Ma
Christopher Matthews
Hajime MOTOYOSHI
Colin O'bryan
Kentaro YAJI
Naoki Yoshikawa
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55299676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3233857(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3233857T3 publication Critical patent/PL3233857T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PL15831150T 2014-12-18 2015-12-17 Stałe postacie skondensowanych heteroaromatycznych pirolidynonów PL3233857T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462093564P 2014-12-18 2014-12-18
US201562115223P 2015-02-12 2015-02-12
US201562180222P 2015-06-16 2015-06-16
EP15831150.6A EP3233857B1 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones
PCT/IB2015/002489 WO2016097862A2 (en) 2014-12-18 2015-12-17 Solid state forms of fused heteroaromatic pyrrolidinones

Publications (1)

Publication Number Publication Date
PL3233857T3 true PL3233857T3 (pl) 2020-07-27

Family

ID=55299676

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15831150T PL3233857T3 (pl) 2014-12-18 2015-12-17 Stałe postacie skondensowanych heteroaromatycznych pirolidynonów

Country Status (29)

Country Link
US (3) US10676473B2 (pl)
EP (2) EP3677582B1 (pl)
JP (3) JP6778195B2 (pl)
KR (1) KR102037502B1 (pl)
CN (1) CN107108609B (pl)
AU (1) AU2015365580B2 (pl)
BR (1) BR112017013149B1 (pl)
CA (1) CA2970864C (pl)
CL (1) CL2017001561A1 (pl)
CO (1) CO2017005910A2 (pl)
CR (1) CR20170249A (pl)
DK (1) DK3233857T3 (pl)
DO (1) DOP2017000130A (pl)
EA (1) EA032291B1 (pl)
EC (1) ECSP17038100A (pl)
ES (1) ES2788454T3 (pl)
GE (2) GEAP201914545A (pl)
IL (1) IL252941B (pl)
MX (1) MX373586B (pl)
MY (1) MY199935A (pl)
NZ (1) NZ732371A (pl)
PE (1) PE20171179A1 (pl)
PH (1) PH12017501123A1 (pl)
PL (1) PL3233857T3 (pl)
SG (1) SG11201701911QA (pl)
TN (1) TN2017000080A1 (pl)
UA (1) UA120632C2 (pl)
WO (1) WO2016097862A2 (pl)
ZA (1) ZA201701800B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY199935A (en) * 2014-12-18 2023-11-29 Wells Therapeutics Inc Solid state forms of fused heteroaromatic pyrrolidinones
WO2018013239A1 (en) * 2016-07-13 2018-01-18 Takeda Pharmaceutical Company Limited Combination of spleen tyrosine kinase inhibitors and other therapeutic agents
CA3079292A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
WO2019088039A1 (en) 2017-10-30 2019-05-09 Takeda Pharmaceutical Company Limited Treatment of acute myeloid leukemia
MY208604A (en) * 2018-12-14 2025-05-20 Chia Tai Tianqing Pharmaceutical Group Co Ltd Salt of syk inhibitor and crystalline form thereof
JP2022519383A (ja) 2019-02-07 2022-03-23 ヤンセン バイオテツク，インコーポレーテツド ジヒドロオロト酸デヒドロゲナーゼ阻害剤
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2021070132A1 (en) 2019-10-10 2021-04-15 Janssen Biotech, Inc. Bi-aryl dihydroorotate dehydrogenase inhibitors
JP7554829B2 (ja) 2019-12-19 2024-09-20 ヤンセン ファーマシューティカ エヌ．ベー． 置換直鎖スピロ誘導体
WO2022074534A1 (en) 2020-10-05 2022-04-14 Janssen Biotech, Inc. Combinations of dihydroorotate dehydrogenase inhibitors and hypomethylating agents
WO2022127753A1 (zh) * 2020-12-18 2022-06-23 山东轩竹医药科技有限公司 稠环类AhR抑制剂
MX2023013436A (es) 2021-05-11 2023-12-12 Janssen Pharmaceutica Nv Terapias de combinacion.
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR102539612B1 (ko) 2021-12-24 2023-06-02 엘에스일렉트릭(주) IP 기반 RAPIEnet을 지원하는 통신 디바이스 및 이를 포함하는 네트워크 시스템
CN120322230A (zh) 2022-11-30 2025-07-15 詹森药业有限公司 包含多发性内分泌癌蛋白-mll抑制剂和至少一种其他治疗剂的组合
EP4626427A1 (en) 2022-11-30 2025-10-08 Janssen Pharmaceutica NV Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5400388B2 (ja) * 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
JP6026525B2 (ja) * 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
TW201625263A (zh) * 2014-09-24 2016-07-16 千禧製藥公司 利用ＰＩ３Ｋα抑制劑與紫杉烷之組合治療
MY199935A (en) * 2014-12-18 2023-11-29 Wells Therapeutics Inc Solid state forms of fused heteroaromatic pyrrolidinones

Also Published As

Publication number Publication date
KR102037502B1 (ko) 2019-10-28
EP3677582B1 (en) 2023-01-25
DOP2017000130A (es) 2017-07-15
ES2788454T3 (es) 2020-10-21
US11352355B2 (en) 2022-06-07
JP6974534B2 (ja) 2021-12-01
AU2015365580B2 (en) 2020-04-02
MX2017007162A (es) 2017-08-28
HK1243406A1 (zh) 2018-07-13
IL252941A0 (en) 2017-08-31
CN107108609A (zh) 2017-08-29
DK3233857T3 (da) 2020-04-27
ZA201701800B (en) 2020-05-27
BR112017013149A2 (pt) 2018-04-10
IL252941B (en) 2020-11-30
MY199935A (en) 2023-11-29
EA032291B1 (ru) 2019-05-31
AU2015365580A1 (en) 2017-07-06
WO2016097862A3 (en) 2016-08-11
CN107108609B (zh) 2020-02-18
EP3233857A2 (en) 2017-10-25
US20200339573A1 (en) 2020-10-29
CA2970864C (en) 2020-04-14
CA2970864A1 (en) 2016-06-23
JP2017537969A (ja) 2017-12-21
US20230348461A1 (en) 2023-11-02
JP2020143081A (ja) 2020-09-10
WO2016097862A2 (en) 2016-06-23
CL2017001561A1 (es) 2018-01-12
GEAP201914545A (en) 2019-08-12
SG11201701911QA (en) 2017-04-27
UA120632C2 (uk) 2020-01-10
CR20170249A (es) 2017-09-25
TN2017000080A1 (en) 2018-07-04
US10676473B2 (en) 2020-06-09
EA201791369A1 (ru) 2017-10-31
EP3677582A1 (en) 2020-07-08
CO2017005910A2 (es) 2017-10-20
JP2022017477A (ja) 2022-01-25
EP3233857B1 (en) 2020-03-11
JP6778195B2 (ja) 2020-10-28
ECSP17038100A (es) 2017-12-01
PE20171179A1 (es) 2017-08-22
PH12017501123A1 (en) 2017-11-27
NZ732371A (en) 2023-04-28
GEP20197050B (en) 2019-12-10
US20160176869A1 (en) 2016-06-23
MX373586B (es) 2020-05-05
KR20170095374A (ko) 2017-08-22
BR112017013149B1 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
IL252941A0 (en) Solid state forms of conjugated heteroaromatic pyrrolidinones
IL258180B (en) Heterocyclic compounds and their uses
SG11201605654QA (en) Fused heterocyclic compound
IL248312A0 (en) suspension element
SG11201605417QA (en) Heterocyclic compounds
IL247018A0 (en) Heterocyclic compound
IL257026A (en) Solid state forms of eluxadoline
EP3133075A4 (en) Fused heterocyclic compound
HU4602U (en) Set of saggar assembly
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL251695A0 (en) Heterocyclic compound
GB201411526D0 (en) Powder
IL265628A (en) Solid state forms of valbenazine
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201606077B (en) Pyrazines modulators of gpr6
ZA201706282B (en) Solid forms of menaquinols
ZA201606598B (en) Novel fused imidazobenzothiazole compounds
HU4603U (en) Set of saggar assembly
IL246569A0 (en) Solid forms of tenofovir
GB201600630D0 (en) Powder formation
GB201416351D0 (en) Heterocyclic derivatives
IL254666A0 (en) Crystalline forms of Aldecalcitol
IL249332A0 (en) Crystalline forms of sofosbuvir
GB2557903B (en) Suspension element
GB201421944D0 (en) Suspension bridges